Bessemer Group
NXTC icon

Bessemer Group’s NextCure NXTC Stock Holding History

Bessemer Group’s Portfolio NXTC Stock Details NXTC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-817
Closed -$210K – 1571
2020
Q2 		$210K Buy
+817
New +$311K ﹤0.01% 1140

Other funds holding NXTC

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
CPX
Canaan Partners X Menlo Park, California $74.7M AUM 151.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
VOYA Investment Management
VOYA Investment Management Atlanta, Georgia $96.1B AUM 40.06% 1-Year Est. Return

Bessemer Group's NXTC Position: Q3 2020 in Review

Bessemer Group sold out of NextCure (NXTC) in Q3 2020, closing a stake of 817 shares — an estimated $210K sold.

Bessemer Group first reported a position in NXTC in Q2 2020 and held it in 1 quarter. The position peaked at $210K in Q2 2020. 75 funds tracked by Wall St. Rank hold NXTC as of Q3 2020.

  • Bessemer Group reported no remaining NextCure position as of Q3 2020 after selling out during the quarter.
  • Bessemer Group sold 817 NextCure shares in Q3 2020, an estimated $210K.
  • Bessemer Group first reported a position in NextCure in Q2 2020 and held it in 1 quarter.
  • Bessemer Group's NextCure position peaked at $210K in Q2 2020.
  • 75 funds tracked by Wall St. Rank held NextCure as of Q3 2020.

Based on Bessemer Group's 13F filing for Q3 2020, filed 12 Nov 2020.